Women facing ovarian, cervical, and endometrial cancers may soon benefit from a fundamentally different therapeutic approach that transforms DNA itself into both medicine and delivery vehicle. This convergence of molecular programming with nanotechnology promises to overcome the toxic side effects and resistance patterns that plague conventional cancer treatments. The innovation centers on DNA nanotherapeutics—engineered genetic constructs that function simultaneously as therapeutic agents and precision delivery systems. These platforms operate through multiple mechanisms: DNA vaccines that train immune systems to recognize HPV-related cervical cancers and tumor-specific antigens, CRISPR gene editing that corrects oncogenic mutations directly within cancer cells, and therapeutic DNA delivery that restores crucial tumor suppressor proteins like p53 and PTEN. Perhaps most intriguingly, DNA origami techniques enable the construction of programmable nanostructures that can carry therapeutic payloads to specific cellular targets while minimizing damage to healthy tissues. This represents a significant departure from traditional approaches that rely on broad-spectrum interventions. The therapeutic potential extends beyond single-target strategies, as these systems can be programmed to address the complex, multi-pathway nature of gynecological cancers. However, this research remains primarily preclinical, with substantial translation hurdles ahead including delivery efficiency, immune system evasion, and manufacturing scalability. While promising as a proof-of-concept for programmable cancer medicine, widespread clinical application likely requires years of additional development to address safety profiles and optimize therapeutic dosing in human patients.